<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858425</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-NICL-COV-1</org_study_id>
    <nct_id>NCT04858425</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection</brief_title>
  <acronym>RESERVOIR</acronym>
  <official_title>A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AzurRx BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AzurRx BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled&#xD;
      study in adults with COVID-19 with gastrointestinal infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>Day 1 to 6 weeks</time_frame>
    <description>Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TEAE</measure>
    <time_frame>Day 1 to 6 weeks</time_frame>
    <description>Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Laboratory Tests including CBC, BUN, blood sugar, electrolytes</measure>
    <time_frame>Day 1 to Day 43</time_frame>
    <description>Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal RNA virus Clearance</measure>
    <time_frame>Day 1 to 6 weeks</time_frame>
    <description>Time to fecal viral RNA clearance (stool sample) assessed by RT-qPCR in the niclosamide arm compared to the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>Day 1 to 6 weeks</time_frame>
    <description>Proportion of patients with each clinical severity score as recommended by the World Health Organization (WHO) for COVID-19 studies by study visit;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Diarrhea</measure>
    <time_frame>Day 1 to 6 weeks</time_frame>
    <description>Time from the first dose of study treatment to the last loose or watery stool in patients with loose or watery stool (Bristol Stool Scale Types 5-7).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Niclosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niclosamide tablets 400 mg 3 times daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets 3 times daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Niclosamide tablets 400 mg 3 times daily for 14 days</description>
    <arm_group_label>Niclosamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo tablets 400 mg 3 times daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Part 1 only, patients with a primary diagnosis of COVID-19, with or without pneumonia,&#xD;
             who agree to be monitored daily for at least 7 days after randomization and who accept&#xD;
             continuing to be assessed for the study procedures.&#xD;
&#xD;
          2. Part 2 only, patients with a primary diagnosis of COVID-19, with or without pneumonia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. At the time of randomization, patients who require intensive care unit (ICU) admission&#xD;
             or patients with severe respiratory insufficiency who require mechanical ventilation&#xD;
             or with rapid worsening of respiratory function leading to expectation for mechanical&#xD;
             ventilation or ICU admission.&#xD;
&#xD;
          2. Evidence of rapid clinical deterioration or existence of any life-threatening&#xD;
             co-morbidity or any other medical condition that, in the opinion of the investigator,&#xD;
             makes the patient unsuitable for inclusion.&#xD;
&#xD;
          3. Patients who, at the time of enrollment, are not in a clinical condition compatible&#xD;
             with the oral administration of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ansy Mathews</last_name>
    <phone>430-268-4344</phone>
    <email>amathews@firstwavebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jasper Summit Research, LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Sherer</last_name>
      <phone>205-387-7555</phone>
      <email>donna@sleepfirst.biz</email>
    </contact>
    <investigator>
      <last_name>Jan Westerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physicians Research Group II, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Atrostic</last_name>
      <phone>800-774-1534</phone>
      <phone_ext>710</phone_ext>
    </contact>
    <investigator>
      <last_name>Allan Soo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208-1004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Boudreau</last_name>
      <phone>941-896-4948</phone>
    </contact>
    <investigator>
      <last_name>Patrick Weston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midland Florida Clinical Research Center, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720-0920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Ann Villaruel</last_name>
      <phone>386-279-6181</phone>
    </contact>
    <investigator>
      <last_name>Godson Oguchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Generation Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016-1895</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Hernandez</last_name>
      <phone>305-828-9100</phone>
      <email>maureenh@ngmresearch.com</email>
    </contact>
    <investigator>
      <last_name>Karelia Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014-2476</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamile Sanchez</last_name>
      <phone>786-362-5763</phone>
      <email>ysanchez@lakesresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LCC Medical Reserach Institute, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Salinas</last_name>
      <phone>305-400-0814</phone>
    </contact>
    <investigator>
      <last_name>Yamirka Duardo-Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yisell Carus</last_name>
      <phone>305-433-6496</phone>
      <email>ycarus@miamiclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Keila Hoover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P &amp; S Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175-2912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Pena</last_name>
      <phone>786-703-2570</phone>
      <email>psresearch15@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Snake River Research, PLLC</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Morrison</last_name>
      <phone>208-535-8404</phone>
    </contact>
    <investigator>
      <last_name>Richard A Nathan, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research</name>
      <address>
        <city>Homestead Meadows</city>
        <state>Texas</state>
        <zip>33032-8225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daydene Ordaz</last_name>
    </contact>
    <contact_backup>
      <phone>(305) 246-0873</phone>
      <email>dordaz@associatesinresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilberto Seco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMS Clinical Research LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Hernanez</last_name>
      <phone>972-216-5100</phone>
    </contact>
    <investigator>
      <last_name>Salma Saiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tranquil Research</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Christian</last_name>
      <phone>713-907-6054</phone>
    </contact>
    <investigator>
      <last_name>Joseph Varon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>50003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akhil Kumar</last_name>
      <phone>+91 9966166070</phone>
    </contact>
    <investigator>
      <last_name>Gangadhar Reddy Mallu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SSG Hospital and Medical Institute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikunj Patel</last_name>
      <phone>+91 9164636137</phone>
    </contact>
    <investigator>
      <last_name>Keyur Brahme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GMERS Medical College and Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390021</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikunj Patel</last_name>
      <phone>+91 9164636137</phone>
    </contact>
    <investigator>
      <last_name>Chirag Chandrakant Rathod</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Private Limited</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Sangle</last_name>
      <phone>+91 9850136436</phone>
    </contact>
    <investigator>
      <last_name>Aparna Kodre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>Nagar</city>
        <state>New Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anshul Kumar</last_name>
      <phone>+91 9818288194</phone>
    </contact>
    <investigator>
      <last_name>Pooja Khosla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maharaja Agrasen Superspeciality Hospital, Jaipur</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302039</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khushwant Khatri</last_name>
      <phone>+91 9414414834</phone>
    </contact>
    <investigator>
      <last_name>Manishkumar Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malla Reddy Narayana Multispecialty Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500055</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitin Shingri</last_name>
      <phone>+91 6364898825</phone>
    </contact>
    <investigator>
      <last_name>Archana Andhavarapu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Medical Enterprise &quot;Likarnya Prydniprovska&quot;</name>
      <address>
        <city>Kremenchug</city>
        <state>Poltava</state>
        <zip>39600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganna Terentieva</last_name>
      <phone>+38 (050) 6690367</phone>
      <email>anna.terentieva@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Nonna Nekroienko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital # 4&quot; of Dnipro City Council</name>
      <address>
        <city>Dnipro</city>
        <zip>41102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Fomichova</last_name>
      <phone>+38 (097) 0316633</phone>
      <email>f.n.s@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Viktoriia Rodionova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Fishchuk</last_name>
      <phone>+38 (050) 4332119</phone>
      <email>fishchukroman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olena Kobrynska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise City Clinical Hospital 13 of Kharkiv Regional Council</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaroslava Zhurikhina</last_name>
      <phone>+38 (066) 6220613</phone>
      <email>yara.zhurikhina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tetiana Ashcheulova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Enterprise Private Manufacturing Company Acinus</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Teroshyna</last_name>
      <phone>+38 (066) 9637258</phone>
      <email>teroshynaacinus@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tetiana Yurkiv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid</keyword>
  <keyword>Covid19 Diarrhea</keyword>
  <keyword>Covid19 GI Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

